CD274 and head and neck squamous cell carcinoma: Immune checkpoint inhibitors of PD-(L)1 represent a significant breakthrough in the treatment of HNSCC in the R/M setting because of the prolonged responses observed with a near doubling of the 2-year survival in the Keynote-048 study.